Research indicates that combining AS-IV with ginsenoside Rg1, ginsenoside Rb1, or notoginsenoside R1 provides superior protection against cerebral ischemia/reperfusion (I/R) injury through multiple mechanisms compared to the effects of individual compounds
This formula features antioxidant-rich ingredients designed to promote cellular vitality and maintain healthy metabolism
Usage: Administration: Typically administered via intramuscular (IM) or intravenous (IV) injection by a qualified healthcare professional
The known risks associated with these medicines are reflected in their FDA-approved product labeling which, collectively, FDA has reviewed more than 40 times and are discussed in textbooks, treatment guidelines and journals. Novo Nordisk updates product labels in cooperation with the FDA and consistent with federal regulations to reflect the most current understanding of the safety and efficacy profile of our medicines, said Flavia Brakling, a spokesperson for the company
To address this, researchers analysed electronic health record data from the TriNetX global research network, incorporating 67 healthcare organisations across the USA